In consequence, the combined assessment of SSCL-16 syndrome scores and IgM levels apparently enables the early identification of that 20–30% subgroup of patients for whom the inflammatory response system might be a target for therapeutic intervention. This evidence concerns the gene CD40LG and Down syndrome.